Today: 2 July 2026

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Singapore, February 7, 2026, 15:11 SGT — Market closed. Keppel Ltd closed out Friday at S$11.64, ticking up 0.17%. With the weekend break in play, traders are watching to see if momentum from its results sticks when trading resumes. According to a filing, Keppel repurchased 151,400 shares on Feb. 6, paying between S$11.38 and S$11.55 a share, for a total outlay of about S$1.74 million with costs factored in.
7 February 2026
·
Singtel share price cools after STT GDC deal surge, with earnings date now in focus

Singtel share price cools after STT GDC deal surge, with earnings date now in focus

Singapore, Feb 7, 2026, 14:55 — Market closed. Singapore Telecommunications Ltd slipped 1.3% to S$4.72 by Friday’s close, notching a third straight fall after touching a new high earlier this week following its data centre deal with KKR. Singapore markets are off for the weekend, leaving traders waiting to see on Monday if buyers step in—or if the drop sticks.
7 February 2026
··
Xero share price slides 14% in a week — what to watch next for ASX:XRO

Xero share price slides 14% in a week — what to watch next for ASX:XRO

Sydney, Feb 7, 2026, 17:12 — The market has closed. Xero Ltd dipped 0.4% to finish at A$81.76 on Friday, keeping the accounting software group parked close to its 52-week lows before the ASX opens again on Monday. Shares moved between A$79.25 and A$82.16 during the day, still feeling the effects of a turbulent week. https://www.investing.com/equities/xero
7 February 2026
·
1 … 502 503 504 505 506 … 2,129

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop